VEGFxPD-(L)1 Multispecifics Report
Following the release of standout data for ivonescimab and surge in recent deals between major biopharma such as Summit Therapeutics and Pfizer clinical collaboration, we have analysed the emergence of VEGFxPD-(L)1 multispecifics.
With exclusive data from Beacon, this review contains:
- Insights into the potential of VEGFxPD-(L)1 multispecifics becoming the new standard of care in lung cancer
- Analysis of the combination therapies that are being evaluated in VEGFxPD-(L)1 clinical trials
- An overview of the VEGFxPD-(L)1 licensing deals between major biopharma companies
You May Also Be Interested In…
Learn More About Oncology
What is Beacon Oncology?
- The Most Comprehensive Way to Search the Oncology Drug Development Landscape: Unique search ontologies based on Oncology drug and trial characteristics
- Market Leading Approach to Oncology Preclinical & Clinical Data Curation: Manual curation of key Oncology research and development data points by Oncology research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Oncology company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
